anti-CD22 immunotoxin RFB4 (scFv)-PE
CAT#: AGTO-L048E
This immunotoxin was achieved by conjugating/fusing the Anti-CD22 scFv to Pseudomonas exotoxin. It was expressed in CHO and purified with affinity chromatography. The immunotoxin selectively binds to leukemia cells and enters cells by receptor-mediated endocytosis, then PE cleaved fragments the size of Mr 37000 and 27000, the large fragment and finally into the Golgi and elongation factor 2 (EM) combining it glycosylation inactivation, inhibition of protein synthesis, leading to apoptosis. It was designed for treatment of leukemia.
Gene Expression
Normal Tissue
Figure 1 Lymph node
Germinal center cells
Staining: Medium
Intensity: Moderate
Quantity: 75%-25%
Location: Cytoplasmic/membranous
* Image credit: Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/2418/6101_A_7_8.jpg
Normal Tissue
Figure 2 Spleen
Cells in red pulp
Staining: Medium
Intensity: Strong
Quantity: <25%
Location: Cytoplasmic/membranous
Cells in white pulp
Staining: High
Intensity: Strong
Quantity: 75%-25%
Location: Cytoplasmic/membranous
* Image credit: Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/2418/6101_B_7_4.jpg
RNA Expression
Figure 3 RNA cell line category: Cell line enhanced (Daudi, REH, U-698, WM-115)
Cell lines ordered by descending RNA expression order.
* Image credit: Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000012124-CD22
❮
❯
Specifications
- Host Species
- Mouse
- Species Reactivity
- Human
- Clone
- RFB4
- Molecule Class
- scFv-PE
- Toxin Description
- Pseudomonas aeruginosa exotoxin (Pseudomonas Aeruginosa Exotoxin A, PE) is a cell toxin produced by P. aeruginosa. Divided into three domains in space. DomainIII (s 405~613 amino acids) having ADP ribosylation activity, can inhibit protein synthesis, PE on toxicity mechanisms of cell depends on its Domainlll. After PE molecules into mammals, Domain Ia and widely distributed in mammalian cells α 2 macroglobulin receptor binding was endocytic, then PE cleaved fragments the size of Mr 37000 and 27000, the large fragment and finally into the Golgi and elongation factor 2 (EM) combining it glycosylation inactivation, inhibition of protein synthesis, leading to apoptosis.
- Applications
- This product is suitable for use in cytotoxicity assay, functional assay and immunotherapy.
- Related Disease
- Leukemia
Target
- Alternative Names
- CD22; CD22 antigen; Lyb8; Lyb-8; A530093D23; B-cell receptor CD22; BL-CAM; siglec-2; T-cell surface antigen Leu-14; B-lymphocyte cell adhesion molecule; sialic acid-binding Ig-like lectin 2; Leukemia; Pseudomonas exotoxin; Pseudomonas exotoxin A; Pseudomonas aeruginosa exotoxin; Pseudomonas aeruginosa exotoxin A; PE; PE38; PE40; ETA; PE33; PE35
- Gene ID
- 12483
- UniProt ID
- P35329
REVIEWS AND Q&AS
CITATIONS
RESOURCES
DOWNLOADS
RELATED PRODUCTS
Inquiry
Navs
Customer Review
There are currently no Customer reviews or questions for AGTO-L048E. Click the button above to contact us or submit your feedback about this product.
Effective Targeting Tool
We used Anti-CD22 Immunotoxin RFB4 in our B-cell lymphomas and observed substantial cytotoxicity. The specificity for CD22 was remarkable, and off-target effects were minimal, leading to clearer results in our xenograft models.
High Potency
The potency of the immunotoxin was evident in our in vitro experiments. It effectively induced apoptosis in CD22-expressing cells, proving to be a valuable tool for our B-cell malignancy studies.
Minimal Off-Target Effects
Off-target effects were a concern, but this immunotoxin showed minimal adverse effects on non-CD22 cells. It reflects well on its design and utility for specific targeting.
Q&As
-
How does the scFv fragment contribute to the efficacy of this immunotoxin?
A: The scFv (single-chain variable fragment) allows for strong and specific binding to the CD22 antigen, enhancing the targeted toxicity and improving the specificity of the immunotoxin against B-cell tumors.
-
What type of experimental controls should be used with Anti-CD22 Immunotoxin RFB4 (scFv)-PE?
A: Negative controls like irrelevant scFv or non-binding immunotoxin should be used alongside untreated samples to validate the target-specific cytotoxic effects.
-
How does the immunotoxin's specificity impact off-target effects?
A: The high specificity due to the scFv reduces off-target effects, minimizing damage to non-B cells and thus lowering potential systemic toxicity.
View the frequently asked questions answered by Creative Biolabs Support.
Submit Your Publication
Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.
Downloadable Resources
Download resources about recombinant antibody development and antibody engineering to boost your research.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Datasheet
MSDS
COA
Certificate of Analysis LookupTo download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number:
See other products for "Clone RFB4"
- CAT
- Product Name
See other products for "CD22"
Select a product category from the dropdown menu below to view related products.
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-047-F(E) | Anti-Human CD22 Recombinant Antibody Fab Fragment(Bectumomab) | ELISA, FC, IP, FuncS, IF, Neut, WB | Fab' - G2a - kappa |
| TAB-1728CL | Anti-Human CD22 Recombinant Antibody (RFB4) | IF, FC | |
| TAB-003LC-S(P) | Mouse Anti-Human CD22 Recombinant Antibody scFv Fragment | FC | |
| TAB-004LC-S(P) | Anti-Human CD22 Recombinant Antibody scFv Fragment | FC | |
| TAB-005LC-S(P) | Mouse Anti-CD22 Recombinant Antibody; scFv Fragment (TAB-005LC-S(P)) | FC | Mouse scFv |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-899 | Humanized Anti-CD22 Recombinant Antibody (clone Pinatuzumab) | FC, IP, ELISA, Neut, FuncS, IF, ICC | Humanized (from mouse) IgG1, κ |
| TAB-1725CL | Human Anti-CD22 Recombinant Antibody (TAB-1725CL) | Block, Cyt, ELISA, FuncS | Humanized IgG |
| TAB-1729CL | Human Anti-CD22 Recombinant Antibody (TAB-1729CL) | IF, FC | Humanized IgG |
| TAB-002LC | Anti-Human CD22 Recombinant Antibody (VM1000) | FC, ELISA, SPR, FuncS | Humanized antibody |
| TAB-002LC-S(P) | Anti-Human CD22 Recombinant Antibody scFv Fragment (VM1000) | ELISA, SPR | Humanized antibody |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| AGTO-G077E | Anti-CD22 immunotoxin RFB4 (IgG)-PE | Cytotoxicity assay, Function study | |
| AGTO-L048D | anti-CD22 immunotoxin RFB4 (scFv)-DT | Cytotoxicity assay, Functional assay | |
| AGTO-L048G | anti-CD22 immunotoxin RFB4 (scFv)-Gel | Cytotoxicity assay, Functional assay | |
| AGTO-L048R | anti-CD22 immunotoxin RFB4 (scFv)-RTA | Cytotoxicity assay, Functional assay | |
| AGTO-L048S | anti-CD22 immunotoxin RFB4 (scFv)-Sap | Cytotoxicity assay, Functional assay |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-1715CL | Human Anti-CD22 Recombinant Antibody (TAB-1715CL) | Cyt, FuncS | Fully human antibody |
| TAB-1716CL | Human Anti-CD22 Recombinant Antibody (TAB-1716CL) | Cyt, FuncS | Fully human antibody |
| TAB-1717CL | Human Anti-CD22 Recombinant Antibody (TAB-1717CL) | Cyt, FuncS | Fully human antibody |
| TAB-1718CL | Human Anti-CD22 Recombinant Antibody (TAB-1718CL) | Cyt, FuncS | Fully human antibody |
| TAB-1719CL | Human Anti-CD22 Recombinant Antibody (TAB-1719CL) | ELISA | Fully human antibody |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-1724CL | Human Anti-CD22 Recombinant Antibody (TAB-1724CL) | Inhib | Chimeric (mouse/human) IgG1, κ |
| TAB-1724CL-S(P) | Mouse Anti-CD22 Recombinant Antibody; scFv Fragment (TAB-1724CL-S(P)) | Inhib | Mouse scFv |
| TAB-001LC | Human Anti-CD22 Recombinant Antibody (TAB-001LC) | ELISA | Chimeric antibody (mouse/human) |
| TAB-001LC-S(P) | Mouse Anti-CD22 Recombinant Antibody; scFv Fragment (TAB-001LC-S(P)) | ELISA | Mouse scFv |
| TAB-001LC-F(E) | Human Anti-CD22 Recombinant Antibody; Fab Fragment (TAB-001LC-F(E)) | ELISA | Chimeric antibody (mouse/human) |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| Gly-001LC | Recombinant Anti-Human CD22 Antibody (Fab glycosylation) | ELISA, FC | Mouse antibody |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| Gly-111LC | Recombinant Anti-Human CD22 Antibody (Fc glycosylation) | ELISA | Chimeric antibody (mouse/human) |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| NEUT-315CQ | Rat Anti-CD22 Recombinant Antibody (clone 2D6) | Block | Rat IgG1, κ |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOR-0545 | Hi-Affi™ Rabbit Anti-CD22 Recombinant Antibody (clone DS545AB) | IP, WB | Rabbit IgG |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-0194-LSX-F(E) | Mouse Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0194-LSX-F(E)) | ELISA | Mouse Fab |
| HPAB-0195-LSX-F(E) | Human Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0195-LSX-F(E)) | ELISA | Human Fab |
| HPAB-0196-LSX-F(E) | Mouse Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0196-LSX-F(E)) | ELISA | Mouse Fab |
| HPAB-0197-LSX-F(E) | Human Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0197-LSX-F(E)) | ELISA | Human Fab |
| HPAB-0198-LSX-F(E) | Mouse Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0198-LSX-F(E)) | ELISA, FC | Mouse Fab |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| FAMAB-0046YC | Mouse Anti-CD22 Recombinant Antibody (clone m5/44) | ELISA, Cyt | Mouse IgG1 |
| FAMAB-0047YC | Human Anti-CD22 Recombinant Antibody (clone g5/44) | ELISA, Cyt | Humanized IgG4 |
| FAMAB-0048YC | Human Anti-CD22 Recombinant Antibody (clone ch5/44) | ELISA | Chimeric (mouse/human) IgG |
| ZG-0022U | Rabbit Anti-CD22 Recombinant Antibody (clone 3D8) | ELISA, IHC | Rabbit IgG |
| VS3-XY235 | Mouse Anti-CD22 Recombinant Antibody (clone 1A3A11) | ELISA, WB, ICC, FC | Mouse IgG1 |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-N0324-YC-S(P) | Mouse Anti-CD22 Recombinant Antibody; scFv Fragment (HPAB-N0324-YC-S(P)) | FuncS | Mouse scFv |
| HPAB-N0325-YC-S(P) | Mouse Anti-CD22 Recombinant Antibody; scFv Fragment (HPAB-N0325-YC-S(P)) | FuncS | Mouse scFv |
| HPAB-0249-FY-S(P) | Recombinant Human Anti-CD22 Antibody scFv Fragment | F | Human scFv |
| HPAB-0034-YJ-S(P) | Mouse Anti-CD22 Recombinant Antibody (clone HB22-23); scFv Fragment | Block | Mouse scFv |
| HPAB-0709-FY-F(E) | Mouse Anti-CD22 Recombinant Antibody (clone AB008); scFv Fragment | ELISA | Mouse scFv |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| AFC-TAB-176 | Afuco™ Anti-CD22 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-176) | IF, IP, Neut, FuncS, ELISA, FC | ADCC enhanced antibody |
| AFC-TAB-198 | Afuco™ Anti-CD22 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-198) | ELISA, FC, IP, FuncS, IF, Neut | ADCC enhanced antibody |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| VS-0424-XY50 | AbPlus™ Anti-CD22 Magnetic Beads (DM13) | IP, Protein Purification | |
| VS-0724-YC918 | AbPlus™ Anti-Cd22 Magnetic Beads (VS-0724-YC918) | IP, Protein Purification |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| VS-0225-XY24 | CytoStream™ Mouse Anti-CD22 Recombinant Antibody (VS-0225-XY24) | FC | Mouse IgG1, kappa |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| VS-0325-XY357 | Anti-CD22 Immunohistochemistry Kit | IHC | |
| VS-0525-XY1143 | Anti-Human CD22 Immunohistochemistry Kit | IHC |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| VS-0425-FY82 | Human Anti-CD22 (clone Inotuzumab) scFv-Fc Chimera | ELISA | Human IgG4, scFv-Fc |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| VS-0425-YC225 | Recombinant Anti-CD22 Vesicular Antibody, EV Displayed (VS-0425-YC225) | ELISA, FC, Neut, Cell-uptake |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| VS-0525-YC201 | Recombinant Anti-CD22 (Epitope A x Epitope B) Biparatopic Antibody, Tandem scFv | ELISA, FC, ICC, IF, IP, Neut | Tandem scFv |
Specific Inquiry
Add to compare
See Our Custom Production in Action
Popular Products
Application: FC, IP, ELISA, Neut, FuncS, IF, IHC
Application: WB, FuncS, IF, Neut, ELISA, FC, IP
Application: ELISA, IP, FC, FuncS, Neut, IF, WB
Application: ELISA, IP, FC, FuncS, Neut, IF, ICC
-2.png)
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: FC, IP, ELISA, Neut, FuncS, IF, ICC
Application: WB, Neut, ELISA, IF, IP, FuncS, FC
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
![Figure 2 Anti-Human CD19 Recombinant Antibody Fab Fragment [TAB-1611CL-F(E)] in HPLC](https://img.creativebiolabs.net/productimages/COA-TAB-1611CL-F(E)-2.png)
Application: Depletion, FuncS
-2.png)
Application: WB, ELISA, FC, IHC, IP
Application: FC, ADCC, CDC, Inhib
Application: Neut, ELISA, IF, IP, FuncS, FC
Application: ELISA, FC, FuncS
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
